INTERVIEW: Novo Downplays Afrezza, Pins Hopes On Oral Pipeline
This article was originally published in PharmAsia News
Novo Nordisk appears not to be worried about any market impact from Afrezza, MannKind’s recently approved inhalable insulin. In an exclusive interview in Copenhagen, the Danish company’s leadership told PharmAsia News that it had taken sufficient steps to maintain its stronghold on the global insulin market.
You may also be interested in...
Sanofi appears to be an ideal match to sell MannKind’s inhaled insulin Afrezza, but the terms of the exclusive worldwide licensing agreement for the product reflect its high-risk nature.
MannKind’s inhaled insulin resulted in a lesser degree of hemoglobin A1c reduction than Novo Nordisk’s insulin aspart in a pivotal study in type 1 diabetics.
FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.